# A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT00890240** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 18 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Attention Deficit Disorders With Hyperactivity

## Interventions

- **DRUG:** JNJ-31001074

## Key facts

- **NCT ID:** NCT00890240
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2010-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890240, "A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00890240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*